The Future of Psychedelic Medicine

Our Story

Find out what inspires us to support mental health disorders.

Our Mission

Supporting innovative therapies to help humans thrive.

Our Team

Multi-Disciplinary Collaboration
creating positive experiences and outcomes.


Using a foundation of evidence-informed research, we want to empower people to achieve their potential and thrive.



Psychedelic medicine is the frontier of mental health and wellness

Social attitudes and behaviours towards mental health are shifting away from pharmaceuticals in favour of sustainably resourced compounds derived from fungi and plant medicines.

350 Million

People globally are affected by a form of depression.

1 Trillion

Dollars lost annually in global workforce productivity due to depression and anxiety.


Formulas standardized across clinical studies of psychedelic compounds.

Havn Life is part of a global community taking an active role in formulations and research for microdosing therapies which have shown effectiveness in addressing mental health and performance.

Press Releases

Havn Life Sciences to support the first modern psilocybin depression study in Germany with MIND Foundation

The research will be led by Prof. Dr. Gerhard Gründer, the only confirmed scientist developing a study to work with psychedelics in Germany since the …

Read More →
Press Releases

Havn Life Sciences earns Health Canada approval for natural health product formulations

The initial six approved formulations were developed to enhance human performance and cognitive health Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE …

Read More →
Press Releases

Havn Life Sciences signs agreement to supply psychedelic compounds for use in research and development to Revive Therapeutics

Havn Life will export naturally derived psilocybin to the United States, for use in IND-enabling studies and future clinical trials under FDA guidelines Vancouver, BC …

Read More →
Scroll to Top